Ruizhen Regenerative Medicine Technology

Guangzhou Ruizhen Regenerative Medicine Technology Co., Ltd., operating as Regen Therapeutics, is a biopharmaceutical firm established in January 2019 by a team of scientists in Guangzhou. The company focuses on the clinical translation of regenerative medicine, with a core emphasis on induced pluripotent stem cell (iPSC) technology. The legal representative, Chairman, and General Manager is Zhang Ling.

The company's operations are vertically integrated, encompassing research, production, and sales aimed at clinical stem cell therapy, drug development, and personalized precision medicine. Regen Therapeutics has established a comprehensive technology platform that covers the entire iPSC cell therapy process, including iPSC reprogramming and cell banking, differentiation techniques for immune and nerve cells, and gene modification for creating engineered iPS cell lines. This infrastructure is housed within a 2,500-square-meter GMP-grade cell production and R&D center, capable of meeting cell demands through Phase II clinical trials and storing thousands of standardized stem cell resources. A key milestone for the company was receiving the first patent authorization in China for its independently developed technology for differentiating dopamine precursor cells, which has shown promising therapeutic effects in primate models of Parkinson's disease.

Regen Therapeutics pursues a dual business model. It provides one-stop research services to pharmaceutical companies, medical institutions, and scientific research organizations, offering iPSC reprogramming and storage, iPSC-derived functional cells, and the production of exosomes and organoids. Concurrently, the company develops its own proprietary pipeline of universal, off-the-shelf cell therapy products derived from iPSCs for treating oncological and neurological disorders. Key pipelines include iDA-001 for Parkinson's disease, iNK001, a natural killer cell line for tumor immunotherapy, and an iMSN pipeline targeting the rare Huntington's disease. In May 2025, the company secured nearly CNY 100 million in a Pre-A financing round to advance these pipelines, particularly to support the IND application and investigator-initiated trials (IIT) for its Parkinson's treatment.

Keywords: regenerative medicine, induced pluripotent stem cells, iPSC, cell therapy, drug development, precision medicine, Parkinson's disease, tumor immunotherapy, natural killer cells, Huntington's disease, neurological disorders, oncology, gene editing, cell banking, GMP manufacturing, clinical translation, iDA-001, iNK001, organoids, biopharmaceutical